View Document Preview and Link Document Date: 2014-11-06 23:50:00 Open Document File Size: 341,09 KB Share Result on Facebook
City Dublin / Morris / Dysport / Canberra / / Company Patient Total / Allergan Australia Pty Ltd / / Country Australia / / Currency USD / / Event FDA Phase / Person Communication and Meetings / / Facility Bibliography Australian Institute of Health / / IndustryTerm draft protocol / final protocol / botulinum toxin products / health insurer / health insurance / clinical management algorithm / healthcare resources / draft decision analytic protocol / / MarketIndex MBS / / MedicalCondition overactive bladder / moderate urinary incontinence / bilateral blepharospasm / headaches / Hemifacial spasm / headache / urinary retention / bladder dysfunction / urge incontinence / urinary incontinence / ambulant cerebral palsy / spasmodic dysphonia / dysfunction / post-injection urinary retention / ambulant paediatric cerebral palsy / refractory overactive bladder / deformity / multiple sclerosis / bladder stones / benign prostatic hyperplasia / clinical syndrome / urinary tract infections / equinovarus / idiopathic overactive bladder / overactive detrusor / slight urinary incontinence / spinal cord injury / urinary urge incontinence / dynamic equinovarus / dynamic foot deformity / cerebral palsy / spasmodic torticollis / foot deformity / urethral stricture / cervical dystonia / blepharospasm / pelvic tumours / stroke / migraine / juvenile cerebral palsy / specifically hemifacial spasm / coughing / Refractory idiopathic urge urinary incontinence / chronic migraine / VII nerve disorders / strabismus / defined neurological illness / dystonia / benign blepharospasm / bladder spasms / severe primary hyperhidrosis / / MedicalTreatment behavioural therapies / antibiotics / retreatment / physiotherapy / BOTOX / occupational therapy / drug therapies / TENS / / Organization Pharmaceutical Benefits Advisory Committee / National Science Foundation / Therapeutic Goods Administration / Australian Government / Bibliography Australian Institute of Health and Welfare / Medicare / Australian Institute of Health and Welfare / Department of Health / Medical Services Advisory Committee / / Person Ageing / Nitti / / Position Minister / Anaesthetist / Governor / / Product Intravesical injection / PERIURETHRAL OR TRANSURETHRAL INJECTION / oxytrol / tolterodine / BOTOX® (botulinum toxin) / BOTOX® / / ProvinceOrState Arkansas / / RadioStation Clin N Am 37 / / Technology draft decision analytic protocol / ultrasound / draft protocol / clinical management algorithm / 1272 Final Decision Analytic Protocol / final protocol / / URL http / SocialTag 
1272 Final Decision Analytic Protocol (DAP) to guide the assessment of intravesical injection of BOTOX® (botulinum toxin) for the treatment of urinary incontinence due to idiopathic detrusor overactivity (IDO)